Bristol Myers Squibb received U.S. FDA approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) co-formulated with Halozyme’s ENHANZE drug delivery technology for subcutaneous use in most previously approved adult, solid tumor intravenous (IV) Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. Opdivo Qvantig is the first and only subcutaneously adm...